Structural Heart Interventions: TAVI, Mitral and Tricuspid Therapies
Structural heart disease has become one of the most rapidly evolving areas of modern cardiovascular medicine. Advances in imaging, catheter-based technology, device engineering, and multidisciplinary decision-making have created treatment options for patients who previously faced limited choices because of age, frailty, surgical risk, or complex anatomy.
Among the most important developments are transcatheter aortic valve implantation (TAVI), mitral transcatheter therapies, and emerging tricuspid interventions. These approaches are changing how clinicians evaluate and treat valvular heart disease while placing greater emphasis on individualized treatment and lifetime cardiovascular care.
The 2025 ESC/EACTS Guidelines for valvular heart disease highlight the central role of multidisciplinary Heart Teams, specialized Heart Valve Centres, advanced imaging, and individualized selection between surgical and transcatheter procedures.
The Evolution of Structural Heart Medicine
Traditional treatment of severe valvular disease has relied heavily on open-heart surgery. Surgical valve replacement and repair remain essential treatments, particularly for younger patients, lower-risk individuals, and patients with anatomy that is unsuitable for catheter-based procedures.
However, the development of transcatheter techniques has created additional possibilities. Instead of opening the chest and placing a patient on cardiopulmonary bypass, selected procedures can be performed through vascular access or other minimally invasive approaches.
The goal is not simply to replace surgery with catheter-based treatment. Rather, structural heart medicine seeks to identify the most appropriate therapy for each patient based on anatomy, age, procedural risk, life expectancy, comorbidities, expected durability, and patient preferences.
TAVI and the Transformation of Aortic Valve Treatment
TAVI has become one of the most significant innovations in structural cardiology. The procedure involves delivering a bioprosthetic valve through a catheter and positioning it within the diseased aortic valve.
TAVI is particularly important for patients with severe aortic stenosis who may have increased surgical risk. Advances in valve design, delivery systems, imaging, and procedural planning have progressively expanded the population considered for transcatheter treatment.
The latest ESC/EACTS recommendations have refined the selection of TAVI versus surgical aortic valve replacement. For patients with a tricuspid aortic valve, TAVI is recommended as the primary treatment modality in many patients aged 70 years or older when anatomy is suitable and transfemoral access is feasible, while surgical replacement remains important for younger patients and selected individuals.
This shift demonstrates how age, anatomy, procedural risk, expected lifespan, and future treatment possibilities must all be considered when selecting a valve intervention.
The Importance of Advanced Imaging
Imaging is at the heart of structural intervention. Echocardiography, computed tomography, fluoroscopy, and other imaging technologies help clinicians understand valve anatomy and plan procedures with increasing precision.
Before TAVI, for example, detailed imaging can help assess the aortic valve, annulus, coronary artery position, vascular access, and surrounding structures. Similar imaging strategies are essential for mitral and tricuspid interventions.
The 2025 ESC/EACTS guidelines place particular emphasis on advanced diagnostic imaging and accurate assessment of the cause and mechanism of valvular disease.
Better imaging can improve patient selection, procedural planning, device positioning, and recognition of potential complications.
Mitral Valve Interventions
Mitral valve disease presents unique challenges because of the complex three-dimensional anatomy of the mitral apparatus. Treatment may involve surgical repair, surgical replacement, or transcatheter approaches depending on the underlying disease and patient characteristics.
Transcatheter edge-to-edge repair (TEER) has become an important option for selected patients with mitral regurgitation, particularly those who are symptomatic and considered high risk for conventional surgery.
In primary mitral regurgitation, surgical repair remains an important standard treatment for appropriate surgical candidates. However, transcatheter approaches can provide an alternative for selected patients who have elevated procedural risk.
For secondary mitral regurgitation, treatment decisions can be even more complex because the valve problem may be related to underlying left ventricular or atrial disease. The latest guidelines distinguish between different forms of secondary mitral regurgitation and have strengthened the role of TEER in carefully selected patients.
Tricuspid Valve Therapies
The tricuspid valve has historically received less attention than the aortic and mitral valves. That situation is changing rapidly.
Severe tricuspid regurgitation can lead to right-sided heart failure, fluid retention, liver and kidney dysfunction, reduced exercise capacity, and impaired quality of life. Earlier recognition and referral are increasingly important because advanced right ventricular dysfunction can make intervention more challenging.
Modern transcatheter options include tricuspid TEER and transcatheter tricuspid valve replacement. According to the 2025 ESC/EACTS recommendations, transcatheter tricuspid interventions should be considered in selected symptomatic high-risk patients when severe right ventricular dysfunction and certain forms of pulmonary hypertension are absent.
This represents an important development because many patients previously had limited minimally invasive treatment options for severe tricuspid disease.
The Role of the Heart Team
Structural heart interventions require collaboration between multiple specialists. Cardiologists, interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiologists, nurses, and other healthcare professionals may contribute to treatment planning.
The Heart Team evaluates not only whether an intervention is technically possible but also whether it is appropriate for the patient's overall clinical situation.
The 2025 ESC/EACTS guidelines emphasize that complex structural procedures should be concentrated in experienced Heart Valve Centres with appropriate expertise and multidisciplinary resources.
This approach can be particularly important for patients with multiple valve diseases, previous valve procedures, complex anatomy, impaired ventricular function, or significant comorbidities.
The Future of Structural Heart Interventions
The field continues to move toward less invasive, more precise, and increasingly personalized therapies. New valve designs, improved delivery systems, artificial intelligence, three-dimensional imaging, computational planning, and advanced procedural guidance may further expand treatment possibilities.
Future structural heart programs may increasingly use patient-specific imaging and digital technologies to predict procedural outcomes before intervention. Device durability and lifetime management will also remain important considerations as transcatheter therapies are offered to younger and lower-risk populations.
The development of valve-in-valve procedures, valve-in-ring interventions, paravalvular leak closure, complex mitral procedures, and emerging tricuspid technologies demonstrates how quickly the structural heart field is expanding.
Conclusion
Structural heart interventions are transforming the management of valvular cardiovascular disease. TAVI has reshaped the treatment of aortic stenosis, mitral TEER has expanded options for selected patients with mitral regurgitation, and transcatheter tricuspid therapies are opening a new chapter in the management of right-sided valve disease.
The future of structural cardiology will depend on combining advanced technology with careful patient selection, high-quality imaging, multidisciplinary Heart Team decision-making, and long-term follow-up.
As innovation continues, the central objective remains clear: provide the right intervention, for the right patient, at the right time, while improving survival, functional capacity, and quality of life.
Sponsorship Opportunities
Connect your organization with leading cardiologists, cardiovascular researchers, healthcare professionals, medical innovators, and industry experts at Cardiology Summit-2027.
Explore Sponsorship & Partnership Opportunities:
https://www.cardiovascular.theiconicmeetings.com/sponsorship
This article is newly written for Blogger.com. It is intended for educational and scientific communication and should not be used as individualized medical advice.
Comments
Post a Comment